Back to top
more

Mirati Therapeutics, Inc. (MRTX)

(Delayed Data from NSDQ)

$63.93 USD

63.93
353,481

+2.52 (4.10%)

Updated May 3, 2019 04:00 PM ET

After-Market: $64.05 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC

by Zacks Equity Research

Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.

Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation

by Zacks Equity Research

Bristol Myers' (BMY) repotrectinib is under review in the European Union for the treatment of locally advanced or metastatic ROS1-Positive NSCLC and NTRK-positive solid tumors.

FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras

by Zacks Equity Research

Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.

Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B

by Zacks Equity Research

Bristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its already established oncology portfolio. The transaction is expected to close in the first half of 2024.

Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B

by Zacks Equity Research

Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

Bristol Myers (BMY) Partners With SystImmune for Oncology Drug

by Zacks Equity Research

Bristol Myers (BMY) is set to co-develop and co-commercialize oncology candidate BL-B01D1 in the United States with SystImmune.

Will Bristol Myers' (BMY) Efforts to Boost Portfolio be Enough?

by Zacks Equity Research

Shares of Bristol Myers (BMY) have been impacted by pipeline bottlenecks and its key drugs face generic competition. We take a look at the company's efforts to counter these.

Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations

by Zacks Equity Research

Mirati (MRTX) posts mixed third-quarter results as the bottom line exceeds estimates while the top line misses.

Ginkgo (DNA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Ginkgo's (DNA) third-quarter earnings call, investor focus is likely to be on the sales performance of its two business units ¿¿¿ Biosecurity and Cell Engineering.

Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Catalyst's (CPRX) third-quarter 2023 earnings are expected to have been driven by the robust performances of its two marketed drugs, Firdapse and Fycompa CIII.

Biogen (BIIB) to Report Q3 Earnings: Will It Beat Estimates?

by Zacks Equity Research

Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.

Bristol-Myers (BMY) Q3 Earnings & Sales Beat, Opdivo Sales Grow

by Zacks Equity Research

Bristol-Myers' (BMY) third-quarter 2023 earnings and sales beat estimates as Opdivo and new products offset losses due to oncology drug Revlimid's generic erosion.

What's in Store for Bristol-Myers (BMY) in Q3 Earnings?

by Zacks Equity Research

Investors are likely to focus on Opdivo's demand along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results.

Ekta Bagri headshot

Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback

by Ekta Bagri

Acquisition and pipeline updates from Bristol Myers (BMY) and Akero Therapeutics (AKRO) are in focus in the biotech sector.

The Zacks Analyst Blog Highlights Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer

by Zacks Equity Research

Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer are part of the Zacks top Analyst Blog.

Kinjel Shah headshot

Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus

by Kinjel Shah

The M&A trend of 2023 shows that there is an increasing interest in biotech companies making innovative cancer treatments.

Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why

by Zacks Equity Research

The upside in Tango's (TNGX) shares can be attributed to the company's progress with its pipeline candidates. A recent acquisition offer for a biotech making similar drugs also bolstered this surge.

Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B

by Zacks Equity Research

Bristol Myers (BMY) to offset its declining revenues from top drugs with the acquisition of Mirati Therapeutics, which will add lung cancer drug Krazati to its portfolio.

Mirati (MRTX) Gets Buyout Offer From Bristol Myers for $4.8B

by Zacks Equity Research

Sanofi (SNY) is set to acquire Mirati (MRTX) for $58 per share in cash along with a contingent value right of $12 per share, tied to a regulatory milestone.

Mirati (MRTX) Surges 45% as Sanofi Reportedly Eyes Buyout

by Zacks Equity Research

A Bloomberg article suggests that pharma giant Sanofi (SNY) is exploring a potential acquisition deal for small cancer drugmaker Mirati Therapeutics (MRTX).

Mirati (MRTX) Soars 12.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Mirati (MRTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Mirati (MRTX) Q2 Earnings Beat, Stock Up on Solid Krazati Sales

by Zacks Equity Research

Mirati (MRTX) reports better-than-expected second-quarter earnings while revenues miss by a slight margin. Its CEO steps down. The stock climbs 9%.